Corporate Showcase Presentations

6:15–6:45 pm
Thursday, September 13

Key Considerations for the Only FDA-Approved oral TPO Receptor Agonist for the Treatment of Chronic ITP in Patients 1 year and Older

While childhood immune thrombocytopenia (ITP) may spontaneously resolve, children who develop chronic ITP are often at significant risk for bleeding and may require treatment. In this program, we will present and discuss treatment options approved for use in pediatric patients with ITP. Objectives include:
  • Discuss the unique activity of an agent in the context of disease pathophysiology
  • Review efficacy and safety data
  • Review dosing and administration

novartis

 

Venue:
Exhibit Hall Theater
Speaker:
Katie Atkinson, FNP
New York-Presbyterian Hospital
Weill Cornell Medical College
7:15–7:45 pm
Thursday,September 13

AFSTYLA and IDELVION: Challenging the Paradigm in Hemophilia

This program offers you the opportunity to:

  • Discuss current challenges in hemophilia A and B treatment 
  • Explore the features and benefits of both AFSTYLA and IDELVION
  • Discover valuable resources, tools, and support
  • Examine a case-based approach to hemophilia A and B
  • Share experiences, ask questions, and gain valuable information which will enable you to better treat patients with hemophilia A and B

CSL Berring

Venue:
Exhibit Hall Theater
Speaker:
Claudio Sandoval, MD
1:50–2:20 pm
Friday, September 14

Diagnosing aHUS: A Pediatric Patient Case Journey

Description: Follow along the patient journey as atypical hemolytic uremic syndrome (aHUS) is diagnosed and review of the clinical decisions, supporting information, and clinical data that arise during this journey. The objectives of this talk include:

  • Describing the clinical considerations in the diagnosis of aHUS and distinguish aHUS from other thrombotic microangiopathies (TMA) with similar clinical presentations
  • Increasing the confidence in diagnosing aHUS associated with a complement-amplifying condition and recognize the importance of the ADAMTS13 assay and the timing of that assay
  • Recognizing the limitations of plasma therapy in aHUS
  • Understanding the factors that inform long-term management of patients with aHUS 

Alexion

Venue:
Exhibit Hall Theater
Speaker:
Dr. Nirmish Shah, MD
Assistant Professor of Medicine
Division of Hematology
Division of Pediatric Hematology/Oncology
Duke University School of Medicine
4:20–4:50 pm
Friday, September, 14

Care with Confidence: Preparing for your Next High-Risk Neuroblastoma Patient

During this session, we will prepare to educate high-risk neuroblastoma patients and families with confidence, have insightful conversations with providers, and better support one another at the bedside.

Come to learn from each other as we discuss tools and resources to help support you when caring for this patient population.

United Therapeutics

Venue:
Exhibit Hall Theater
Speaker:
Theresa C. DiSipio, MSN CPNP-AC CPHON®